免疫检查点抑制剂治疗驱动基因阴性非小细胞肺癌脑转移的研究进展  

Research progress of immune checkpoint inhibitors in the treatment of brain metastasis of gene negative non-small cell lung cancer

作　　者：赵文华[1] 曾爱屏[1] Zhao Wenhua;Zeng Aiping(Department of Respiratory Oncology,Guangxi Medical University Affiliated Tumor Hospital,Nanning 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院呼吸肿瘤内科,南宁530021

出　　处：《广西医科大学学报》2022年第8期1326-1333,共8页Journal of Guangxi Medical University

基　　金：国家自然科学基金资助项目(No.81660357);广西医疗卫生适宜技术开发与推广应用项目(No.S2019049);吴阶平医学基金会临床科研专项资助基金(No.320.6750.19088-65);北京医卫健康公益基金会医学科学研究基金资助项目(No.TA201901)。

摘　　要：脑转移(BM)是非小细胞肺癌(NSCLC)常见的的转移部位且是导致患者预后不良的重要原因。放疗等局部治疗仍是驱动基因阴性的NSCLC脑转移患者主要治疗方式,而免疫检查点抑制剂(ICIs)在临床上逐渐显示出获益的趋势。ICIs单药(PD-1抑制剂、PD-L1抑制剂、CTLA-4抑制剂)、ICIs联合化疗、抗血管生成治疗以及ICIs联合ICIs等治疗模式都显示了一定的颅内疗效及较好的安全性,但这些方案的优化,获益人群的确定还需要进一步讨论。该文将对ICIs在驱动基因阴性NSCLC脑转移患者中的理论基础、应用进展和挑战作一综述。Brain metastasis(BM)is a common metastatic site of non-small cell lung cancer(NSCLC)and an important cause of poor prognosis.Local therapy such as radiotherapy is still the main treatment for patients with NSCLC brain metastasis with negative driving gene,while immune checkpoint inhibitors(ICIs)gradually show a trend of benefit in clinic.ICIs monotherapy(PD-1 inhibitors,PD-L1 inhibitors,CTLA-4 inhibitors),ICIs combined chemotherapy,antiangiogenic therapy and ICIs combined with ICIs all showed certain intracranial efficacy and safety,but the optimization of these regimens and the identification of beneficiary groups need to be further discussed.This article reviews the theoretical basis,application progress and challenges of ICIs in patients with driving gene negative NSCLC brain metastasis.

关 键 词：免疫检查点抑制剂 非小细胞肺癌 脑转移 

分 类 号：R734.2[医药卫生—肿瘤]